Skip to main content

Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

 

Corporate Presentation IDEAYA Highlights Investor Alerts

 
Recent News
Mar 12, 2024

­Trial will evaluate IDE161, IDEAYA's investigational PARG inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with MSI-high and MSS endometrial...

Mar 4, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor...

Feb 20, 2024

Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored study...

All Releases

Stock Info
NASDAQIDYA

Stock Information

Events
Tuesday, March 12, 2024
8:00am EDT

Panel: "Novel Targeted-Oncology: Approaches, Advancements, & Future Directions", with participation by Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology

Monday, March 11, 2024
12:40pm EDT

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Andrew Berens, M.D., Senior Managing Director, Targeted Oncology

All Events

WE ARE DEDICATED TO

Improving Lives Through Transformative Precision Medicines

INVESTOR INSIGHTS

Close Menu